These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23873419)

  • 1. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Wiecek A
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
    Kuczera P; Adamczak M; Wiecek A
    Kidney Blood Press Res; 2016; 41(1):1-8. PubMed ID: 26751580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
    Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
    Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cinacalcet in the therapy of secondary hyperparathyroidism--own experiences].
    Nowak Z; Konieczna M; Saracyn M; Baczyński D; Wesolowski P; Waińkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):303-6. PubMed ID: 18634360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    BMC Nephrol; 2016 Nov; 17(1):176. PubMed ID: 27846800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
    Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum parathyroid hormone concentrations measured by chemiluminescence and electrochemiluminescence methods — are the results comparable in haemodialysis patients with chronic kidney disease?
    Kuczera P; Maszczyk A; Machura E; Kurzak E; Adamczak M; Więcek A
    Endokrynol Pol; 2015; 66(3):219-23. PubMed ID: 26136130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.